Physician profile
Erin C Tanner
NPI 1588952774
$140,543.34
in general payments reported to CMS, 2019-2025
40 companies · $77K in 2025
The $77K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,839 · 2022: $11K · 2023: $14K · 2024: $34K · 2025: $77K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $95K · Food and Beverage: $15K · Travel and Lodging: $15K · Education: $99.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $94,668.86 |
| Food and Beverage | $15,180.70 |
| Travel and Lodging | $14,935.11 |
| Education | $99.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $84,217.82 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $18,966.80 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $14,557.93 | 2021-2025 | Linzess |
| Madrigal Pharmaceuticals | $11,885.28 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,623.37 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,058.20 | 2021-2025 | Entyvio |
| Ardelyx, INC. | $834.89 | 2022-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $547.89 | 2023-2025 | Tremfya, Stelara |
| Genzyme Corporation | $484.34 | 2022-2025 | |
| Pfizer INC. | $452.38 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $450.80 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $377.77 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $366.30 | 2021-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $361.04 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $361.01 | 2022-2025 | Dupixent |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $352.76 | 2021-2024 | Dificid |
| Evoke Pharma, INC. | $342.38 | 2021-2025 | Gimoti |
| Redhill Biopharma INC. | $317.04 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $313.14 | 2024-2025 | Zenpep |
| Celgene Corporation | $304.61 | 2021-2024 | Zeposia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.86 | 2023-2025 | Cyltezo |
| Nestle Healthcare Nutrition INC. | $135.85 | 2021-2023 | |
| Lilly USA, LLC | $134.07 | 2023-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $123.96 | 2021-2024 | Rebyota, Clenpiq, Cimzia |
| Lucid Diagnostics INC. | $112.75 | 2024 | |
| Intercept Pharmaceuticals, INC. | $98.91 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $93.68 | 2025 | Iqirvo |
| Organon LLC | $86.43 | 2023-2025 | Renflexis, Hadlima |
| Daiichi Sankyo INC. | $82.93 | 2022 | |
| Intra-Sana Laboratories | $72.61 | 2021-2022 | |
| Braintree Laboratories, INC. | $71.23 | 2021-2023 | Sutab, Suflave |
| Celltrion USA INC. | $44.91 | 2024 | Zymfentra |
| Amgen INC. | $30.47 | 2021 | |
| Enterra Medical, INC. | $26.80 | 2024 | |
| Alexion Pharmaceuticals, INC. | $20.68 | 2022 | |
| Fresenius Kabi USA, LLC | $18.50 | 2023 | Idacio |
| Shield Therapeutics INC | $16.04 | 2024 | |
| Novo Nordisk INC | $15.89 | 2025 | Wegovy |
| Boston Scientific Corporation | $15.58 | 2022 | |
| Abbott Laboratories | $13.44 | 2023 | Cardiomems |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.